kneeEOS completes the company’s EOSapps portfolio of online
weight-bearing 3D surgical planning for the most common orthopedic
PARIS--(BUSINESS WIRE)--EOS imaging (Paris:EOSI)(Euronext, FR0011191766 – EOSI), the pioneer in
2D/3D orthopedic medical imaging, announced today that the Company has
received a 510(k) clearance from the Food and Drug Administration (FDA)
to market kneeEOS software in the United States. The kneeEOS online 3D
planning software utilizes weight-bearing 3D images and data from the
EOS system to provide an optimized surgical plan for Total Knee
Arthroplasty. The software makes an initial automatic proposal for the
size selection and position of the implant components to facilitate
surgical preparation and optimize the alignment in 3D while displaying
relevant clinical parameters in real time.
The clearance of kneeEOS completes the Company’s current portfolio of
EOSapps dedicated to the most common orthopedic surgeries. The EOSapps
are based on a patient’s 2D images and 3D digital anatomical dataset
obtained from an EOS exam. EOS exams are performed at each step of the
patient care continuum including diagnosis, pre-operative planning,
post-operative assessment and follow-up.
Marie Meynadier, CEO of EOS imaging, said, “The kneeEOS FDA clearance
is an important milestone that allows us to offer our full set of
software solutions to the U.S. market. It will support the growing
adoption of EOS images, 3D models and patient-specific datasets at each
step of the care continuum, helping healthcare providers bring the value
of personalized treatments to their patients without the high dose and
cost of CT imaging.”
For more information, please visit www.eos-imaging.com.
EOS imaging has been chosen to be included in the new EnterNext©
PEA-PME 150 index, composed of 150 French companies and listed on
Euronext and Alternext markets in Paris.
EOS imaging is listed on Compartment C of Euronext Paris
FR0011191766 – Ticker: EOSI
About EOS imaging
EOS imaging designs, develops, and markets EOS®, an
innovative medical imaging system dedicated to osteoarticular
pathologies and orthopedics, as well as associated solutions. The
Company is authorized to market in 51 countries, including the United
States, Japan, China, and the European Union. The Group posted 2015
revenues of €21.8 million and employs 122 people. The Group is based in
Paris and has five subsidiaries in Besançon (France), Cambridge
(Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.